OMER – Omeros Corporation
Omeros CorporationOMER
$9.97Name : Omeros Corporation
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $721,582,272.00
EPSttm : 1.15
Omeros Corporation
$9.97
1.22%$0.12
OMER — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
22.84
Margin Of Safety %
Put/Call OI Ratio
0.61
EPS Next Q Diff
-0.84
EPS Last/This Y
0.43
EPS This/Next Y
-0.41
Price
9.96
Target Price
47.5
Analyst Recom
2
Performance Q
-14.86
Upside
12.1%
Beta
2.55
Ticker: OMER
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | OMER | 14.35 | 0.31 | 0.25 | 55318 |
| 2026-05-12 | OMER | 14.77 | 0.31 | 0.29 | 55802 |
| 2026-05-13 | OMER | 14.39 | 0.31 | 0.89 | 56816 |
| 2026-05-14 | OMER | 13.27 | 0.32 | 0.84 | 59246 |
| 2026-05-15 | OMER | 12.24 | 0.32 | 1.22 | 60278 |
| 2026-05-18 | OMER | 11.69 | 0.44 | 0.12 | 41931 |
| 2026-05-19 | OMER | 11.98 | 0.40 | 0.29 | 48740 |
| 2026-05-20 | OMER | 12.39 | 0.40 | 0.25 | 49733 |
| 2026-05-21 | OMER | 11.94 | 0.39 | 0.23 | 52377 |
| 2026-05-22 | OMER | 11.47 | 0.38 | 0.25 | 55223 |
| 2026-05-26 | OMER | 11.64 | 0.39 | 2.58 | 55618 |
| 2026-05-27 | OMER | 11.07 | 0.50 | 0.73 | 60981 |
| 2026-05-28 | OMER | 11.15 | 0.56 | 1.16 | 72784 |
| 2026-05-29 | OMER | 11.02 | 0.56 | 3.39 | 73461 |
| 2026-06-02 | OMER | 10.24 | 0.56 | 0.35 | 76787 |
| 2026-06-03 | OMER | 10.16 | 0.57 | 0.18 | 78092 |
| 2026-06-04 | OMER | 10.25 | 0.55 | 6.93 | 82674 |
| 2026-06-05 | OMER | 9.8 | 0.58 | 2.11 | 83957 |
| 2026-06-08 | OMER | 9.85 | 0.60 | 0.52 | 85658 |
| 2026-06-09 | OMER | 9.96 | 0.61 | 0.47 | 86228 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | OMER | 14.35 | 56.9 | - | -0.53 |
| 2026-05-12 | OMER | 14.77 | 56.9 | - | -0.53 |
| 2026-05-13 | OMER | 14.41 | 56.9 | - | -0.53 |
| 2026-05-14 | OMER | 13.27 | 56.9 | - | -0.53 |
| 2026-05-15 | OMER | 12.25 | 56.9 | - | -0.53 |
| 2026-05-18 | OMER | 11.70 | 56.9 | - | -1.54 |
| 2026-05-19 | OMER | 11.98 | 56.9 | - | -1.54 |
| 2026-05-20 | OMER | 12.39 | 55.8 | - | -1.54 |
| 2026-05-21 | OMER | 11.95 | 55.8 | - | -1.54 |
| 2026-05-22 | OMER | 11.46 | 115.7 | - | 0.42 |
| 2026-05-26 | OMER | 11.63 | 116.3 | - | 0.42 |
| 2026-05-27 | OMER | 11.07 | 116.3 | - | 0.42 |
| 2026-05-28 | OMER | 11.16 | 116.3 | - | 0.42 |
| 2026-05-29 | OMER | 11.03 | 116.3 | - | 0.42 |
| 2026-06-01 | OMER | 10.72 | 149.9 | - | 0.38 |
| 2026-06-02 | OMER | 10.25 | 149.9 | - | 0.38 |
| 2026-06-03 | OMER | 10.16 | 149.9 | - | 0.38 |
| 2026-06-04 | OMER | 10.25 | 149.9 | - | 0.38 |
| 2026-06-05 | OMER | 9.78 | 149.9 | - | 0.38 |
| 2026-06-08 | OMER | 9.85 | 149.9 | - | 0.38 |
| 2026-06-09 | OMER | 9.96 | 149.9 | - | 0.38 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | OMER | -2.12 | 0.74 | 24.41 |
| 2026-05-12 | OMER | -2.12 | 0.74 | 22.81 |
| 2026-05-13 | OMER | -2.12 | 0.74 | 22.81 |
| 2026-05-14 | OMER | -2.12 | 0.74 | 22.81 |
| 2026-05-15 | OMER | -2.12 | 0.74 | 22.81 |
| 2026-05-18 | OMER | -2.11 | 0.07 | 22.67 |
| 2026-05-19 | OMER | -2.15 | 0.07 | 22.67 |
| 2026-05-20 | OMER | -2.15 | 0.07 | 22.67 |
| 2026-05-21 | OMER | -2.15 | 0.07 | 22.67 |
| 2026-05-22 | OMER | -2.15 | 0.07 | 22.67 |
| 2026-05-26 | OMER | -2.15 | -3.39 | 22.67 |
| 2026-05-27 | OMER | -2.15 | -3.39 | 22.67 |
| 2026-05-28 | OMER | -2.41 | -3.39 | 22.89 |
| 2026-05-29 | OMER | -2.41 | -3.39 | 22.89 |
| 2026-06-02 | OMER | -2.41 | -4.08 | 22.89 |
| 2026-06-03 | OMER | -2.41 | -4.08 | 22.89 |
| 2026-06-04 | OMER | -2.41 | -4.08 | 22.89 |
| 2026-06-05 | OMER | -2.41 | -4.08 | 22.84 |
| 2026-06-08 | OMER | -2.54 | -4.10 | 22.84 |
| 2026-06-09 | OMER | -2.54 | -4.10 | 22.84 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.57
Avg. EPS Est. Current Quarter
0.27
Avg. EPS Est. Next Quarter
-0.27
Insider Transactions
-2.54
Institutional Transactions
-4.1
Beta
2.55
Average Sales Estimate Current Quarter
12
Average Sales Estimate Next Quarter
17
Fair Value
Quality Score
56
Growth Score
23
Sentiment Score
38
Actual DrawDown %
43.6
Max Drawdown 5-Year %
-93.4
Target Price
47.5
P/E
11.65
Forward P/E
PEG
P/S
72.96
P/B
P/Free Cash Flow
EPS
0.86
Average EPS Est. Cur. Y
0.38
EPS Next Y. (Est.)
-0.03
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
871.02
Relative Volume
1.15
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
EPS 1 30Days Diff
0.9
EBIT Estimation
◆
OMER
Healthcare
$9.97
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
30.1
Range 1M
7.3%
Sup Dist
3.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
200%
EPS NY
-493.3%
52W%
47.6%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+376.4% upside
Upside
+376.4%
Quality
56
Omeros CorporationSector: Healthcare
Industry: Biotechnology
Employees: 175
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
OMER
Latest News
—
Caricamento notizie per OMER…
stock quote shares OMER – Omeros Corporation Stock Price stock today
news today OMER – Omeros Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch OMER – Omeros Corporation yahoo finance google finance
stock history OMER – Omeros Corporation invest stock market
stock prices OMER premarket after hours
ticker OMER fair value insiders trading